LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more. And the breakthrough technology is not artificial intelligence, it is genomics.

Molecular Biology 88

Molecular Biology Production Drug Development Small Molecule 88

Drug Target Review

FEBRUARY 19, 2024

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. There are many failures and setbacks in drug discovery, and you need a lot of resilience to keep going.

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

Chemical Biology and Drug Design

DECEMBER 6, 2023

However, the pharmacodynamic mechanism and molecular target of SP-FC in the treatment of HS are still unclear. Therefore, this study is intended to explore the mechanism and target of SP-FC in the treatment of HS through network pharmacology combined with in vitro cell and molecular biology experiments. Next, STRING 11.0

Molecular Biology 100

Molecular Biology Protein Expression Treatment Regulations 100

DrugBaron

FEBRUARY 16, 2021

More than a hundred antibodies have now been approved as drugs, making up around a third of all approvals over the last three years. The first technological leap was the invention of hybridoma technology, by César Milstein together with his post-doc Georges Köhler working at the world-famous Laboratory of Molecular Biology in Cambridge.

Molecular Biology 130

Molecular Biology Small Molecule Engineering Laboratories 130

FDA Law Blog: Drug Discovery

MAY 1, 2024

proudly announces the return of attorney Sarah Wicks to its drug development and compliance group. Sarah brings a wealth of experience and a proven track record of advising innovative drug and biologics companies through the intricate landscape of product development and commercialization. Hyman, Phelps & McNamara, P.C.

Drug Development 52

Drug Development Molecular Biology Compliance Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. 25) in the journal Communications Biology. ” The findings published today (Feb.

FDA Approval 52

FDA Approval FDA Molecular Biology Virus 52

BMG Labtech

MARCH 11, 2024

They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research. This is reflected in scientific discoveries across many research disciplines including immunology , molecular biology , medicine, and diagnostics.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Drug Target Review

APRIL 19, 2024

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. Identifying new drugs is an extremely complex project. We are now in the preclinical stage of developing a proprietary drug pipeline.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

Drug Target Review

MARCH 15, 2024

The discovery and development phases of biotherapeutic drugs leverage multiple technologies and processes across upstream and downstream stages of the bioprocess workflow. Selecting the appropriate upstream tools is key to avoiding challenges downstream, ultimately reducing development costs and delays in drug approvals.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. 5 Organoids are recognised as New Alternative Methods (NAMs) in drug development. billion by 2030.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Broad Institute

JANUARY 30, 2024

In his lab at the Broad Institute of MIT and Harvard , he uses genomic technology to explore how bacteria become drug-resistant, to study how the immune system goes awry in sepsis, and to develop new molecular diagnostic approaches for bacterial infections. million deaths attributed directly to resistant infections.

Hospitals 137

Hospitals Virus Medical Schools Science 137

Drug Target Review

NOVEMBER 27, 2023

eFFECTOR Therapeutics has developed a novel class of cancer drugs known as Selective Translation Regulator Inhibitors (STRIs), which directly target the eIF4F complex. These characteristics position STRIs as a promising class of oncology drugs with the potential to significantly impact cancer care and improve patient outcomes.

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

The Pharma Data

NOVEMBER 10, 2021

” Feng said the findings challenge a presently popular approach in perfection drug.”We “Targeting Shp2 as a remedy appears to actually worsen the complaint, at least in the case of Myc- driven hepatocellular melanoma (HCC) or liver cancer,” said Feng. ” Source link: [link].

Disease 52

Disease Molecular Biology RNA Drugs 52

Broad Institute

AUGUST 7, 2023

Drugs that activate STING have been developed and tested in clinical trials as cancer immunotherapy drugs that would help stimulate the immune system to destroy tumors. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway. Online August 3, 2023.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

Drug Target Review

OCTOBER 3, 2024

Since the 1970s, when hybridoma technology enabling the generation of monoclonal antibodies (mAbs) was first developed, 1 antibody-based therapeutics have become one of the most rapidly growing drug categories, with applications across cancer indications, immune disorders and infections.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

Broad Institute

JUNE 21, 2023

said Vamsi Mootha , senior author of the study, an institute member at the Broad, professor of systems biology and medicine at Harvard Medical School, and professor of molecular biology at Massachusetts General Hospital. They supported this hypothesis by using a drug that pharmacologically blocks this response.

Treatment 98

Treatment Disease Molecular Biology Medical Schools 98

Drug Target Review

MAY 27, 2024

How does the company see antibody-drug conjugates (ADCs) fitting into this approach? Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

DrugBank

FEBRUARY 9, 2023

1 Present address: Functional Genomics and Metabolism Research Unit, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark. 3 Research Focus: Network-based drug repositioning strategy to identify drugs targeting obesity and type 2 diabetes. Dutta et al.

Clinical Pharmacology 52

Clinical Pharmacology Molecular Biology DNA Licensing 52

Alta Sciences

JUNE 11, 2024

One thing is for sure—regardless of how the field evolves around regulation requirements, Altasciences has the experience and range of capabilities to take on your gene therapy drug development programs. Connect with Dr. Turcotte on LinkedIn. Image Thumbnail_Blog_June 2024.jpg

Therapies 52

Therapies Molecular Biology Immune Response Science 52

The Pharma Data

MARCH 16, 2022

As Professor Patrick Cramer, Professor at the Max-Planck Institute for Multidisciplinary Sciences and Director of the Molecular Biology Department, emphasized in his congratulatory speech: “Kai Johnsson is a world-leading research scientist in chemical biology.

Cell Biology 52

Cell Biology Molecular Biology Science Laboratories 52

The Pharma Data

NOVEMBER 23, 2020

Food and Drug Administration last year and appears to be on track for a potential regulatory review as a treatment for multiple myeloma next year. as a director of molecular biology. Cilta-cel snagged Breakthrough Therapy Designation from the U.S. Zhu founded Genetastix Corporation, Inc.,

Government 52

Government Molecular Biology Regulations Laboratories 52

Drug Target Review

DECEMBER 7, 2023

Phage have been of interest to scientists as tools to understand fundamental molecular biology, as vectors of horizontal gene transfer and drivers of bacterial evolution, as sources of diagnostic and genetic tools, and as novel therapeutic agents. Infection and Drug Resistance. Bacteriophage. Available from: [link]

RNA 59

RNA Immune Response DNA Molecular Biology 59

The Pharma Data

APRIL 28, 2021

In the past two decades we have learned so much in oncology about the molecular biology of cancer and that has led to better treatments for patients. We want to change the way we develop new immunology drugs and make them more effective and precise for each patient. We want to do the same for immunology.

Molecular Biology 40

Molecular Biology Doctors Disease Treatment 40

DrugBaron

NOVEMBER 22, 2022

As a commercial drug discovery company, much of their progress has been shielded from public gaze, even as they made ground-breaking advances to the technology platform. Over the next seven years, we will see just how much impact these advances can make for drug discovery and development.

Bioinformatics 100

Bioinformatics Regulations Molecular Biology Engineering 100

The Pharma Data

NOVEMBER 22, 2021

It’ll support AstraZeneca’s focus on specialised and perfection drugs and foster the discovery and development of coming generation rectifiers, including nucleotide- grounded, gene-editing and cell curatives. Over the once century, roughly 50 Nobel Prize winners in chemistry and physiology or drug have been associated with Cambridge.

Molecular Biology 52

Molecular Biology Laboratories Engineering Hospitals 52

Elrig

APRIL 6, 2023

Research & Innovation 2023 Roundup Blog Research & Innovation 2023 Roundup Blog It was great to welcome so many people to the Research and Innovation 2023: Accelerating Future Drug Discovery event last week in Hinxton, Cambridge, UK.

Research 40

Research Molecular Biology Science Drugs 40

Drug Target Review

FEBRUARY 28, 2024

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. and MBA students with real-world consulting experiences.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 126

Therapies Virus DNA Clinical Trials 126

Drug Target Review

JUNE 19, 2024

From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JULY 1, 2024

Can you explain the mechanism of action of SRP-001 and how it differs from traditional analgesics like acetaminophen (ApAP) and non-steroidal anti-inflammatory drugs (NSAIDs) in treating acute, chronic and neuropathic pain? We set out to improve health by developing a novel non-opioid that avoids potential abuse.

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

NOVEMBER 18, 2021

Our thing is that BMS’ general support of the three incubators and our specific donation to companies within them will help goad the coming surge of scientific improvements that lead to development of new drugs that ameliorate the lives of people with serious conditions.”. The company is backed by Illumina Accelerator.

Molecular Biology 52

Molecular Biology Pharmaceuticals Laboratories Clinical Development 52

Drug Target Review

JUNE 11, 2024

When choosing my bachelor’s degree, the choice was between pursuing a career in biology or in computer science. Biology won that battle, and I pursued a bachelor’s and master’s degree in biochemistry and molecular biology.

Engineering 64

Engineering Science Molecular Biology Doctors 64

Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. Synta was focused on small molecule drug discovery and development in oncology and inflammatory diseases.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Target Review

AUGUST 29, 2023

While at Flagship Pioneering, I explored the concept of using a tRNA molecule as a drug. in cell and molecular biology with a focus in cancer biology from the Perelman School of Medicine at the University of Pennsylvania. Before joining Flagship, Theonie received her Ph.D.

Science 98

Science Disease Molecular Biology Therapies 98

Drug Target Review

AUGUST 29, 2024

MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs. However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

OCTOBER 25, 2024

8 In what ways does the integration of hypothesis-driven and hypothesis-free approaches enhance our ability to identify novel biomarkers and drug targets for Alzheimer’s disease? Integration” is the key word here, as we need both approaches to enhance identification of biomarkers and drug targets for Alzheimer’s disease. Bennett, D.

Disease 59

Disease Clinical Trials Therapies Science 59